GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hepion Pharmaceuticals Inc (NAS:HEPA) » Definitions » FCF Yield %

Hepion Pharmaceuticals (Hepion Pharmaceuticals) FCF Yield % : -547.45 (As of May. 01, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Hepion Pharmaceuticals FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Hepion Pharmaceuticals's Trailing 12-Month Free Cash Flow is $-40.89 Mil, and Market Cap is $7.47 Mil. Therefore, Hepion Pharmaceuticals's FCF Yield % for today is -547.45%.

The historical rank and industry rank for Hepion Pharmaceuticals's FCF Yield % or its related term are showing as below:

HEPA' s FCF Yield % Range Over the Past 10 Years
Min: -597.62   Med: 0   Max: 0
Current: -547.45


HEPA's FCF Yield % is ranked worse than
96.65% of 1552 companies
in the Biotechnology industry
Industry Median: -14.81 vs HEPA: -547.45

Hepion Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.


Hepion Pharmaceuticals FCF Yield % Historical Data

The historical data trend for Hepion Pharmaceuticals's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hepion Pharmaceuticals FCF Yield % Chart

Hepion Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -37.79 -23.17 -36.08 -152.79 -261.99

Hepion Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -83.84 -55.51 -123.43 -234.66 -230.63

Competitive Comparison of Hepion Pharmaceuticals's FCF Yield %

For the Biotechnology subindustry, Hepion Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hepion Pharmaceuticals's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hepion Pharmaceuticals's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Hepion Pharmaceuticals's FCF Yield % falls into.



Hepion Pharmaceuticals FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Hepion Pharmaceuticals's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-40.903 / 15.6126852
=-261.99%

Hepion Pharmaceuticals's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-9.002 * 4 / 15.6126852
=-230.63%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hepion Pharmaceuticals FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Hepion Pharmaceuticals FCF Yield % Related Terms

Thank you for viewing the detailed overview of Hepion Pharmaceuticals's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Hepion Pharmaceuticals (Hepion Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
399 Thornall Street, First Floor, Edison, NJ, USA, 08837
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.
Executives
Peter Wijngaard director 8 SYLVAN WAY, PARSIPPANY NJ 07054
Robert T Foster officer: Chief Scientific Officer C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Kaouthar Lbiati director 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Anand Reddi director 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
John T Cavan officer: Chief Financial Officer C/O STEMLINE THERAPEUTICS, INC., 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10022
John P Brancaccio director C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Gary S Jacob director, officer: CEO and President
Donald E Garlikov 10 percent owner 41 S. HIGH STREET, SUITE 3400, COLUMBUS OH 43215
Tamar D Howson director
Thomas Phd Adams director
Gabriel Cerrone 10 percent owner VIA SANT' ANDREA 18, MILAN L6 20121
John Z Sullivan-bolyai officer: Chief Medical Officer C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, 1ST FLOOR, EDISON NJ 08837
James Sapirstein director, officer: Chief Executive Officer 1517 SAN JACINTO, HOUSTON TX 77002
Arnold Lippa director C/O AURORA CAPITAL, LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
William Karl Hornung officer: Chief Financial Officer C/O CONTRAVIR PHARMACEUTICALS, INC., 420 LEXINGTON AVE., SUITE 300, NEW YORK NY 10170